{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0049","statisticalMethod":"1-sided stratified log rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The upper limit was not calculable because an insufficient number of participants reached the event at the final time point for assessment.","groupId":"OG000","lowerLimit":"19.4","upperLimit":"NA","value":"26.7"},{"groupId":"OG001","lowerLimit":"11.3","upperLimit":"23.5","value":"15.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"360"},{"groupId":"OG001","value":"357"}],"units":"Participants"}],"description":"Disease free survival (DFS) is defined as the time from documentation of first CR at any time to the first of relapse or death from any cause in participants who achieved a CR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients will receive daunorubicin 60 mg/m\\^2 by IV push days 1-3 plus cytarabine 200 mg/m\\^2 IV days 1-7, and midostaurin 50 mg orally twice daily days 8-21. Participants achieving remission will receive four 28 day cycles of high dose cytarabine (3000 mg/m\\^2) days 1, 3, \\& 5 and midostaurin at 50 mg orally twice daily days 8-14. Maintenance therapy was given to participants who continued in remission for 12 28-day cycles of midostaurin 50 mg orally twice daily.","id":"OG000","title":"Induction and Consolidation Chemotherapy Plus Midostaurin"},{"description":"Patients will receive daunorubicin 60 mg/m\\^2 by IV push days 1-3 plus cytarabine 200 mg/m\\^2 IV days 1-7, and placebo 50 mg orally twice daily days 8-21. Participants achieving remission will receive four 28 day cycles of high dose cytarabine (3000 mg/m\\^2) days 1, 3, \\& 5 and placebo at 50 mg orally twice daily days 8-14. Maintenance therapy was given to participants who continued in remission for 12 28-day cycles of placebo 50 mg orally twice daily.","id":"OG001","title":"Induction and Consolidation Chemotherapy Plus Placebo"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Duration of study (Up to 10 years)","title":"Disease-free Survival (DFS)","type":"SECONDARY","unitOfMeasure":"months"}